Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.
Annabelle D
AD
Donaldson
Raymond C
RC
Chan
Iain B
IB
Gosbell
D000284:Administration, Oral; D000293:Adolescent; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002981:Clindamycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D005269:Femur; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D010019:Osteomyelitis / Q000188:drug therapy*; D016459:Prosthesis-Related Infections / Q000188:drug therapy*; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D005672:Fusidic Acid; D012293:Rifampin